Legacy CG’s Filana Therapeutics FLNA Stock Holding History

Legacy CG’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	-$14K	–	109
2022 Q2	$14K	Buy	+500	New	+$12.6K	0.01%	90

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legacy CG's FLNA Position: Q3 2022 in Review

Legacy CG sold out of Filana Therapeutics (FLNA) in Q3 2022, closing a stake of 500 shares — an estimated $14K sold.

Legacy CG first reported a position in FLNA in Q2 2022 and held it in 1 quarter. The position peaked at $14K in Q2 2022. 175 funds tracked by Wall St. Rank hold FLNA as of Q3 2022.

Legacy CG reported no remaining Filana Therapeutics position as of Q3 2022 after selling out during the quarter.
Legacy CG sold 500 Filana Therapeutics shares in Q3 2022, an estimated $14K.
Legacy CG first reported a position in Filana Therapeutics in Q2 2022 and held it in 1 quarter.
Legacy CG's Filana Therapeutics position peaked at $14K in Q2 2022.
175 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2022.

Based on Legacy CG's 13F filing for Q3 2022, filed 4 Nov 2022.